An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA
- PMID: 20833737
- DOI: 10.1136/ard.2010.132068
An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA
Abstract
Aims: To compare the British Isles Lupus Assessment Group (BILAG) 2004, the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) flare index (SFI) and physician's global assessment (PGA) in assessing flares of disease activity in patients with systemic lupus erythematosus (SLE).
Methods: Sixteen patients with active SLE were assessed by a panel of 16 rheumatologists. The order in which the patients were seen was randomised using a 4×4 Latin square design. Each patient's flare status was determined at each assessment using the BILAG 2004 activity index; the SFI and a PGA. A group of five specialists designated each patient into severe, moderate, mild or no flare categories.
Results: The rate of complete agreement (95% CI) of the four individual examining physicians for any flare versus no flare was 81% (55% to 94%), 75% (49% to 90%) and 75% (49% to 90%) for the BILAG 2004 index, SELENA flare instrument and PGA, respectively. The overall agreement between flare defined by BILAG 2004 and the SFI was 81% and when type of flare was considered was 52%. Intraclass correlation coefficients (95% CI), as a measure of internal reliability, were 0.54 (0.32 to 0.78) for BILAG 2004 flare compared with 0.21 (0.08 to 0.48) for SELENA flare and 0.18 (0.06 to 0.45) for PGA. Severe flare was associated with good agreement between the indices but mild/moderate flare was much less consistent.
Conclusions: The assessment of flare in patients with SLE is challenging. No flare and severe flare are identifiable but further work is needed to optimise the accurate 'capture' of mild and moderate flares.
Similar articles
-
How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.Rheumatology (Oxford). 2014 Dec;53(12):2175-81. doi: 10.1093/rheumatology/keu153. Epub 2014 Apr 11. Rheumatology (Oxford). 2014. PMID: 24729400 Free PMC article.
-
Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.Arthritis Rheum. 2013 Aug;65(8):2143-53. doi: 10.1002/art.37995. Arthritis Rheum. 2013. PMID: 23754628 Clinical Trial.
-
Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients.Arthritis Care Res (Hoboken). 2018 Jan;70(1):98-103. doi: 10.1002/acr.23252. Epub 2017 Dec 8. Arthritis Care Res (Hoboken). 2018. PMID: 28388813 Free PMC article.
-
Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus.Arthritis Care Res (Hoboken). 2011 Sep;63(9):1213-23. doi: 10.1002/acr.20507. Arthritis Care Res (Hoboken). 2011. PMID: 21618452 Free PMC article.
-
The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment.Autoimmun Rev. 2012 Mar;11(5):326-9. doi: 10.1016/j.autrev.2011.06.011. Epub 2011 Sep 18. Autoimmun Rev. 2012. PMID: 21958603 Review.
Cited by
-
Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments.Lupus Sci Med. 2015 Mar 4;2(1):e000075. doi: 10.1136/lupus-2014-000075. eCollection 2015. Lupus Sci Med. 2015. PMID: 25861457 Free PMC article.
-
A leprosy clinical severity scale for erythema nodosum leprosum: An international, multicentre validation study of the ENLIST ENL Severity Scale.PLoS Negl Trop Dis. 2017 Jul 3;11(7):e0005716. doi: 10.1371/journal.pntd.0005716. eCollection 2017 Jul. PLoS Negl Trop Dis. 2017. PMID: 28671966 Free PMC article.
-
Impact of standard of care treatments and disease variables on outcomes in systemic lupus erythematosus trials: analysis from the Lupus Foundation of America Collective Data Analysis Initiative.Eur J Rheumatol. 2016 Mar;3(1):13-19. doi: 10.5152/eurjrheum.2015.0048. Epub 2016 Jan 29. Eur J Rheumatol. 2016. PMID: 27708963 Free PMC article.
-
What Causes Lupus Flares?Curr Rheumatol Rep. 2016 Mar;18(3):14. doi: 10.1007/s11926-016-0562-3. Curr Rheumatol Rep. 2016. PMID: 26951252 Review.
-
Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan.Trials. 2020 Jul 16;21(1):652. doi: 10.1186/s13063-020-04391-2. Trials. 2020. PMID: 32677992 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical